Physician profile
Michael S Benjamin
NPI 1619933132
$14,917.12
in general payments reported to CMS, 2019-2025
61 companies · $2,451 in 2025
The $2,451 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,220 · 2020: $1,650 · 2021: $1,865 · 2022: $1,535 · 2023: $2,585 · 2024: $2,611 · 2025: $2,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,963 · Long Term Medical Supply Or Device Loan: $682 · Education: $2.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,963.40 |
| Long Term Medical Supply Or Device Loan | $681.53 |
| Education | $2.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,431.21 | 2019-2025 | |
| Pfizer INC. | $1,097.60 | 2019-2025 | |
| Janssen Biotech, INC. | $886.95 | 2019-2025 | Tecvayli, Erleada, Talvey |
| Astrazeneca Pharmaceuticals Lp | $850.84 | 2020-2025 | Imfinzi, Calquence, Enhertu |
| Merck Sharp & Dohme LLC | $836.40 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $736.38 | 2019-2024 | Kyprolis, Blincyto, Lumakras |
| Takeda Pharmaceuticals U.S.A., INC. | $638.94 | 2019-2024 | Iclusig, Alunbrig, Ninlaro |
| Genentech USA, INC. | $616.79 | 2019-2025 | Tecentriq, Venclexta, Tecentriq Hybreza |
| Incyte Corporation | $558.31 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Genzyme Corporation | $540.45 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $533.25 | 2019-2025 | Opdualag, Opdivo |
| Astellas Pharma US INC | $407.26 | 2019-2025 | Xtandi, Xospata |
| Gilead Sciences, INC. | $369.65 | 2019-2025 | Trodelvy |
| Celgene Corporation | $339.90 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Seagen INC. | $326.83 | 2019-2023 | Adcetris |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Benjamin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.